Skip to Content

Caplacizumab Pregnancy and Breastfeeding Warnings

Caplacizumab is also known as: Cablivi

Medically reviewed by Last updated on Mar 8, 2019.

Caplacizumab Pregnancy Warnings

Animal studies have failed to reveal evidence of adverse developmental outcomes. There are no controlled data in human pregnancy. However, there are potential risks of hemorrhage in the mother and fetus associated with use of this drug.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

The manufacturer makes no recommendation regarding use during pregnancy.

US FDA pregnancy category: Not assigned.

Risk Summary: Insufficient data exist to inform a drug-associated risk of major birth defects and miscarriage.

-Pregnant women receiving this drug should be carefully monitored for evidence of excessive bleeding.
-This drug may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.

See references

Caplacizumab Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Cablivi (caplacizumab)." Genzyme Corporation, Cambridge, MA.

References for breastfeeding information

  1. "Product Information. Cablivi (caplacizumab)." Genzyme Corporation, Cambridge, MA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.